Asahi Kasei Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AHKSF research report →
Price Chart
About the company
Founded in Tokyo, Japan, in 1922, Asahi Kasei Corporation is a global enterprise engaged in the development, production, and sale of a diverse range of products, organized into three core business areas: Materials, Homes, and Health Care. Its extensive Materials segment encompasses a vast array of chemical and industrial products. This includes fundamental chemicals such as caustic soda, ammonia, and nitric acid, alongside various polymers, chemical intermediates, and specialized additives.
- CEO
- Koshiro Kudo
- IPO
- 2002
- Employees
- 47,895
- HQ
- Tokyo, TY, JP
Get TickerSpark's AI analysis on AHKSF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $13.87B
- P/E
- 11.15
- Fwd P/E
- 0.08
- PEG
- 0.18
- P/S
- 0.67
- P/B
- 1.01
- EV/EBITDA
- 6.04
- Div Yield
- 2.78%
- Gross Margin
- 33.47%
- Op Margin
- 8.19%
- Net Margin
- 6.10%
- ROE
- 9.51%
- ROIC
- 5.03%
Latest fiscal year · YoY change
- Revenue
- $3.09T+1.9%
- Gross Profit
- $1.01T+5.9%
- Op Income
- $232.66B
- Net Income
- $159.79B+18.4%
- EPS
- $118.24+20.7%
- OCF Growth
- +1.2%
- FCF Growth
- +31.8%
- 52W High
- $11.84
- 52W Low
- $7.46
- 50D MA
- $10.21
- 200D MA
- $10.37
- Beta
- 0.66
- RSI (14)
- 66
- Avg Volume
- 492
No earnings-call transcripts are available for AHKSF yet.
- Free Float
- 83.7%
- Shares Outstanding
- 1.35B
- Float Shares
- 1.13B
Our AHKSF coverage
Recent articles, reports, and earnings notes.
No research on AHKSF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AHKSF report →Asahi Kasei Therapeutics Announces First Patient Dosed in Phase 2a Trial of AIC468 for BK Virus Infection in Kidney Transplant Recipients
businesswire.com · Oct 8
Asahi Kasei to Integrate Global Pharmaceutical Brand Under Asahi Kasei Therapeutics
businesswire.com · Sep 29
Asahi Kasei Introduces VANTIJ® SU-VFC Benchtop to Improve Efficiency and Consistency in Gene Therapy Manufacturing
businesswire.com · Sep 15
Asahi Kasei Microdevices' CZ39 and CZ3K Current Sensors Featured in Microchip Technology's Machine Learning-Based Arc Fault Detection Reference Design
businesswire.com · Sep 8
Asahi Kasei Unveils New Wet-Process Separator Coating Line in North Carolina, Advancing the Company's 40-Year North American Battery Separator Strategy
businesswire.com · Aug 26
Asahi Kasei Develops Novel Lithium Pre-doping Technology to Raise Energy Density and Lower Cost of Silicon-rich Lithium-ion Batteries
businesswire.com · Aug 19
Asahi Kasei's Capacity Expansion for Water Electrolysis and Chlor‑Alkali Equipment in Kawasaki Awarded Regional Economic Incentives
businesswire.com · Aug 19
Asahi Kasei Enters First License Agreement for Production and Sale of Acetolyte™ Novel Electrolyte in China
businesswire.com · Aug 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.